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Abstract: Tuberculosis is the leading infectious cause of death
worldwide, with 9.6 million cases and 1.5 million deaths in 2014.
The World Health Organization (WHO) estimates 480,000 cases
were multidrug-resistant (MDR). Less than half of the patients
entered into treatment for MDR-TB successfully complete that
treatment, due primarily to high rates of mortality and loss to
follow-up. These in turn reﬂect weaknesses in current treat-
ment regimens and national tuberculosis programs, coupled with
operational treatment challenges. We here provide an update
on recent developments in the tuberculosis drug-development
pipeline, including new and repurposed antimicrobials and host-
directed agents, as they apply to new regimens to shorten and
improve outcomes of MDR-TB treatment. Several new or repur-
posed antimicrobial drugs are in advanced trials for MDR-TB, and
two new antimicrobial drug candidates are in early trials. Sev-
eral trials to reduce the duration of therapy in both MDR and
drug susceptible tuberculosis are ongoing. A wide range of can-
didate host-directed therapies are currently under development,
to accelerate cure, prevent new drug resistance and prevent per-
manent lung injury. As these agents have been approved for other
clinical indications, they are now ready for repurposing for tuber-
culosis in Phase II clinical trials. At the same time we review risks
associated with evaluation of new treatment regimens, and high-
light opportunities for advancing tuberculosis research generally
throughregulatory innovation inMDR-TB. Progress in tuberculosis-
speciﬁc biomarkers, including culture conversion, PET/CT imaging
and gene expression proﬁles, can support this innovation. Several
global initiatives now provide unique opportunities to tackle the
tuberculosis epidemic through collaborative North-South partner-
ships for clinical trials training and research, allowing funders to
coordinate multiple national and regional programs for greatest
overall impact.
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Abstract: Tuberculosis is amongst the top 10 causes of mortal-
ity in children worldwide. Despite this fact, pediatric TB is not a
priority in most national health programmes. In view of current
Millennium Development Goals recommending a scale-up of pedi-
atric TB detection and management globally, there is a dire need to
improve pediatric TB programmes in high-burden countries.
The diagnosis and management of pediatric TB is challenging.
Tuberculosis in children is paucibacillary and the disease is rarely
bacteriologically conﬁrmed. Suspicion of MDR is based on either
a history of contact with an adult with MDR TB case or clinical
failure on ﬁrst line therapy. It is therefore crucial to consider the
epidemiological proﬁle (i.e., contact with a known MDR-TB index
case, or possible or likely infection in regions with high rates of
DR-TB), or if the patient or index case clinically deteriorates during
therapy despite strictly adhering to therapy. Thismakes case detec-
tion and contact tracing an essential aspect of the management of
pediatric TB. Most research in TB diagnostics is focused on adults.
There is a dire need to invest in improved TB diagnostics in children
particularly in this era of MDR and XDR TB.
Regarding therapeutics, robust information onpharmacokinetic
and pharmacodynamic properties, adverse effects and drug inter-
actions of ATT is lacking in children. Children differ from adults in
the way that drugs are administered, the manner in which they
are metabolized and in the adverse effects experienced. Monitor-
ing and describing adverse effects in children is challenging; young
children cannot hardly available and all these pose challenges in
the treatment of drug resistant TB in children articulate pain, nau-
sea, vertigo, peripheral neuropathy, anxiety or confusion. Rashes
are common due to a variety of etiologies and the testing of hearing
and vision ismore difﬁcult than in adults. Furthermore, regimen for
pediatric MDR treatment and the doses for second line drugs have
not been systematically tested and reported. Pediatric formulations
for second line drugs are hardly available. All the above highlighted
issues pose signiﬁcant challenges in the treatment of drug resistant
TB in children.
Another important issue is the therapeutic choice for children
who are contacts of an adult MDR /XDR TB case. The beneﬁt of
the currently recommended regimens of INH alone or INH plus
rifampicin has not been tested in drug resistant cases. The option of
prophylaxis with ﬂuoroquinolone is recommended for adults but
needs additional research to be included in pediatric guidelines.
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